AbbVie (ABBV) vs Eli Lilly (LLY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Eli Lilly (LLY) has outperformed AbbVie (ABBV) over the past year, gaining 41.8% versus a gain of 16.5%. Over five years, LLY leads with a +402.8% price change compared with +148.2% for ABBV. Eli Lilly is the larger company by market cap ($1.06 trillion vs $479.52 billion), about 2.2 times the size.
On valuation, AbbVie trades at a lower forward P/E (16.7x vs 25.0x for Eli Lilly). AbbVie offers the higher dividend yield (2.52% vs 0.54%). Eli Lilly converts more of its revenue into profit, with a net margin of 31.7% versus 6.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABBV | LLY |
|---|---|---|
| Share price | $271.36 | $1,188.72 |
| Market cap | $479.52B | $1.06T |
| 1-day change | +1.75% | +2.70% |
| YTD return | +18.76% | +11.30% |
| 1-year return | +16.55% | +41.78% |
| 5-year return | +148.20% | +402.83% |
| P/E ratio (TTM) | 76.44 | 39.90 |
| Forward P/E | 16.69 | 24.98 |
| EPS (TTM) | $3.55 | $29.79 |
| Dividend yield | 2.52% | 0.54% |
| Annual dividend | $6.83 | $6.46 |
| Revenue (latest FY) | $61.16B | $65.18B |
| Revenue growth (YoY) | +8.57% | +44.70% |
| Net income (latest FY) | $4.23B | $20.64B |
| Gross margin | 70.24% | 83.04% |
| Operating margin | 24.65% | — |
| Net margin | 6.91% | 31.67% |
| 52-week high | $274.94 | $1,292.65 |
| 52-week low | $190.75 | $783.85 |
| Distance from 52-week high | -1.30% | -8.04% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +3.48% | +11.82% |
| Average volume | 4.86M | 2.48M |
| Shares outstanding | 1.77B | 891.74M |
| Employees | 57,000 | 50,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Eli Lilly is about 2.2 times larger than AbbVie by market value ($1.06T vs $479.52B).
- LLY has outperformed ABBV by 25.2 percentage points over the past year.
- AbbVie trades at a higher earnings multiple (76.4x vs 39.9x trailing P/E).
- AbbVie offers a meaningfully higher dividend yield (2.52% vs 0.54%).
- Eli Lilly is more profitable, keeping 31.7 cents of every revenue dollar as net income versus 6.9 cents for AbbVie.
- Eli Lilly grew revenue faster in its latest fiscal year (+44.70% vs +8.57%).
About AbbVie
ABBV stock →AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 57,000 employees
About Eli Lilly
LLY stock →Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 50,000 employees
ABBV vs LLY FAQ
Which is bigger, AbbVie or Eli Lilly?
Eli Lilly (LLY) is larger, with a market capitalization of $1.06T compared with $479.52B for AbbVie (ABBV).
Which stock has performed better over the past year, ABBV or LLY?
LLY returned +41.78% over the past 12 months, compared with +16.55% for ABBV (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ABBV or LLY?
LLY has the lower trailing P/E at 39.9, versus 76.4 for ABBV. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, AbbVie or Eli Lilly?
AbbVie has the higher yield at 2.52%, compared with 0.54% for Eli Lilly.
Are AbbVie and Eli Lilly in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.